CTOs on the Move


 
Geltor is the bio-design company that makes the world`s most advanced proteins for consumers, with a focus on unique functionality and sustainability.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.geltor.com
  • 1933 Davis St,
    San Leandro, CA USA 94577
  • Phone: 415.325.3560

Executives

Name Title Contact Details

Funding

Geltor raised $18.2M on 10/25/2018
Geltor raised $91.3M on 07/27/2020

Similar Companies

Regenesis Biomedical

Regenesis Biomedical is a Scottsdale, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Biomerieux

Biomerieux is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Promega Corporation

Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The company's 1,450 products enable scientists worldwide to advance their knowledge in genomics, proteomics, cellular analysis,

Aeovian Pharmaceuticals

We are a San Francisco Bay Area-based research stage biopharmaceutical company aiming to discover, develop and commercialize innovative therapeutics for the treatment of rare and age-related diseases. We are developing compounds to modulate molecular pathways that address the underlying causes of disease initiation and progression, such as oxidative, cellular and environmental stress.

Evolve Biosystems

Evolve BioSystems is a spin-out from the Foods For Health Institute (FFHI) at the University of California, Davis. The company builds on more than a decade of research into the infant gut microbiome and its unique interaction with breast milk components, established by the founding scientists including Bruce German, David Mills, Carlito Lebrilla, Daniela Barile and Samara Freeman. Their fundamental research and translational clinical trials have been enabled by more than $15 million in federal and private grants since 2004. Under the leadership of CEO Dr. David Kyle, Evolve completed a $1 million seed funding round in mid-2014, a $9 million Series A round in August 2015 and most recently a $20 million Series B capital raise in 2017. Evolve has now successfully completed a milestone proof-of-concept study to demonstrate the efficacy of its initial proprietary offering, with a series of upcoming trials scheduled across both human and animal health applications. With a strong portfolio of intellectual property developed at UC Davis, a world-class management team plus blue-chip investors, and an unwavering dedication to allowing science to direct our product development, Evolve continues to expand it`s pipeline of next generation microbiome-based solutions to establish, restore, and maintain a healthy gut microbiome.